317 related articles for article (PubMed ID: 10493109)
1. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.
Lee KO; Akil H; Woods JH; Traynor JR
Eur J Pharmacol; 1999 Aug; 378(3):323-30. PubMed ID: 10493109
[TBL] [Abstract][Full Text] [Related]
2. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
3. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method.
Richards ML; Sadée W
Eur J Pharmacol; 1985 Aug; 114(3):343-53. PubMed ID: 2998812
[TBL] [Abstract][Full Text] [Related]
4. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
6. The bovine mu-opioid receptor: cloning of cDNA and pharmacological characterization of the receptor expressed in mammalian cells.
Onoprishvili I; Andria ML; Vilim FS; Hiller JM; Simon EJ
Brain Res Mol Brain Res; 1999 Nov; 73(1-2):129-37. PubMed ID: 10581406
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
Xu H; Wang X; Partilla JS; Bishop-Mathis K; Benaderet TS; Dersch CM; Simpson DS; Prisinzano TE; Rothman RB
Brain Res Bull; 2008 Sep; 77(1):49-54. PubMed ID: 18639745
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
9. Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.
Alt A; Clark MJ; Woods JH; Traynor JR
Br J Pharmacol; 2002 Jan; 135(1):217-25. PubMed ID: 11786497
[TBL] [Abstract][Full Text] [Related]
10. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors.
Shapira M; Vogel Z; Sarne Y
Cell Mol Neurobiol; 2000 Jun; 20(3):291-304. PubMed ID: 10789829
[TBL] [Abstract][Full Text] [Related]
11. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop.
Bonner G; Meng F; Akil H
Eur J Pharmacol; 2000 Sep; 403(1-2):37-44. PubMed ID: 10969141
[TBL] [Abstract][Full Text] [Related]
13. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
14. Differential opioid agonist regulation of the mouse mu opioid receptor.
Blake AD; Bot G; Freeman JC; Reisine T
J Biol Chem; 1997 Jan; 272(2):782-90. PubMed ID: 8995364
[TBL] [Abstract][Full Text] [Related]
15. Mu-delta opioid receptor functional interaction: Insight using receptor-G protein fusions.
Snook LA; Milligan G; Kieffer BL; Massotte D
J Pharmacol Exp Ther; 2006 Aug; 318(2):683-90. PubMed ID: 16690720
[TBL] [Abstract][Full Text] [Related]
16. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
17. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
20. delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice.
Hosohata Y; Vanderah TW; Burkey TH; Ossipov MH; Kovelowski CJ; Sora I; Uhl GR; Zhang X; Rice KC; Roeske WR; Hruby VJ; Yamamura HI; Lai J; Porreca F
Eur J Pharmacol; 2000 Feb; 388(3):241-8. PubMed ID: 10675732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
